Taysha Gene [TSHA] vs Vertex [VRTX] Detailed Stock Comparison

Taysha Gene Therapies Inc.

NASDAQ
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Taysha Gene Therapies Inc. wins in 2 metrics, Vertex Pharmaceuticals Inc. wins in 16 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Taysha Gene Therapies Inc. Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) 2.53 28.40 Taysha Gene Therapies Inc.
Price-to-Book Ratio 7.39 5.92 Vertex Pharmaceuticals Inc.
Debt-to-Equity Ratio 28.41 10.91 Vertex Pharmaceuticals Inc.
PEG Ratio -15.71 0.88 Vertex Pharmaceuticals Inc.
EV/EBITDA -14.53 21.78 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) 0.00% 32.94% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) -515.95% 39.60% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) N/A 39.60% N/A
Return on Equity -68.45% 22.54% Vertex Pharmaceuticals Inc.
Return on Assets (TTM) -27.42% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $-93.83M $3.19B Vertex Pharmaceuticals Inc.
1-Year Return 116.61% 1.24% Taysha Gene Therapies Inc.
Price-to-Sales Ratio (TTM) 188.17 9.22 Vertex Pharmaceuticals Inc.
Enterprise Value $1.59B $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio 162.58 8.83 Vertex Pharmaceuticals Inc.
Gross Profit Margin (TTM) N/A 85.39% N/A
Revenue per Share (TTM) $0 $47 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $-0.34 $15.32 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 1.08 0.37 Vertex Pharmaceuticals Inc.
Short % of Float 13.79% 1.78% Vertex Pharmaceuticals Inc.

Taysha Gene Therapies Inc. vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

TSHA
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Taysha Gene Therapies Inc.-2.46%1.79%-14.31%25.61%40.15%8.38%
Vertex Pharmaceuticals Inc.0.76%-2.49%-1.11%-12.54%-1.86%-5.98%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Taysha Gene Therapies Inc.116.61%643.04%-73.70%-76.01%-76.01%-76.01%
Vertex Pharmaceuticals Inc.1.24%34.08%113.19%376.31%717.28%1,190.86%

Performance & Financial Health Analysis: Taysha Gene Therapies Inc. vs Vertex Pharmaceuticals Inc.

MetricTSHAVRTX
Market Information
Market Cap i$1.84B$109.45B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i3,639,2001,057,061
90 Day Avg. Volume i3,156,5531,272,097
Last Close$5.55$428.34
52 Week Range$2.25 - $7.30$362.50 - $507.92
% from 52W High-23.97%-15.67%
All-Time High$33.35 (Jan 18, 2021)$519.88 (Nov 04, 2024)
% from All-Time High-83.36%-17.61%
Growth Metrics
Quarterly Revenue Growth1.71%0.10%
Quarterly Earnings Growth1.71%0.31%
Financial Health
Profit Margin (TTM) i0.00%0.33%
Operating Margin (TTM) i-5.16%0.40%
Return on Equity (TTM) i-0.68%0.23%
Debt to Equity (MRQ) i28.4110.91
Cash & Liquidity
Book Value per Share (MRQ)$0.87$73.49
Cash per Share (MRQ)$1.11$26.01
Operating Cash Flow (TTM) i$-93,090,000$3.63B
Levered Free Cash Flow (TTM) i$-56,697,624$2.57B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Taysha Gene Therapies Inc. vs Vertex Pharmaceuticals Inc.

MetricTSHA (Apr 26, 2026)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i2.5328.40
Forward P/E i-15.7119.95
PEG Ratio i-15.710.88
Price to Sales (TTM) i188.179.22
Price to Book (MRQ) i7.395.92
Market Capitalization
Market Capitalization i$1.84B$109.45B
Enterprise Value i$1.59B$105.96B
Enterprise Value Metrics
Enterprise to Revenue i162.588.83
Enterprise to EBITDA i-14.5321.78
Risk & Other Metrics
Beta i1.080.37
Book Value per Share (MRQ) i$0.87$73.49

Financial Statements Comparison: Taysha Gene Therapies Inc. vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricTSHA (2025)VRTX (2025)
Revenue/Sales i9.77M12.00B
Cost of Goods Sold iN/A1.65B
COGS % of Revenue i0.0%13.8%
Gross Profit iN/A10.35B
Gross Margin i0.0%86.2%
Research & Development i86.40M4.04B
Operating Income (EBIT) i-110.50M4.55B
Operating Margin i-1,130.6%37.9%
EBITDA i-106.59M5.25B
EBITDA Margin i-1,090.6%43.7%
Pre-Tax Income i-109.00M4.64B
Pre-Tax Income % of Revenue i-1,115.3%38.7%
Income Tax iN/A690.00M
Income Tax % of Revenue i0.0%5.7%
Net Income (Profit) i-109.00M3.95B
Profit Margin i-1,115.3%32.9%

Balance Sheet & Liquidity Metrics

MetricTSHA (2025)VRTX (2025)
Cash & Equivalents i319.77M5.08B
Total Current Assets i324.65M11.20B
Total Current Assets % of Revenue i3,321.9%93.3%
Total Current Liabilities i26.55M3.86B
Total Current Liabilities % of Revenue i271.7%32.2%
Long-Term Debt i68.28M1.95B
Long-Term Debt % of Revenue i698.6%16.3%
Total Shareholders Equity i246.94M18.67B
Retained Earnings i-711.30M13.56B
Retained Earnings % of Revenue i-7,278.2%113.0%
Property, Plant & Equipment i12.75M1.56B

Cash Flow Statement Comparison

MetricTSHA (2025)VRTX (2025)
Operating Cash Flow i-98.84M3.77B
Operating Cash Flow % of Revenue i-1,011.4%31.4%
Capital Expenditures i-738,000-437.60M
Free Cash Flow i-93.83M3.19B
FCF Margin i-960.1%26.6%
Debt Repayment i-40.61M-5.40M
Common Stock Repurchase iN/A-2.39B

Short Interest & Institutional Ownership Analysis

MetricTSHAVRTX
Shares Short i38.92M4.02M
Short Ratio i12.832.80
Short % of Float i13.79%1.78%
Shares Outstanding i285.05M253.99M
Float Shares i198.47M253.24M
% Held by Insiders i10.62%0.21%
% Held by Institutions i94.27%97.60%
% Held by Public i-4.89%2.19%

Dividend Analysis & Yield Comparison: Taysha Gene Therapies Inc. vs Vertex Pharmaceuticals Inc.

MetricTSHAVRTX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A